The effect of erythropoietin (EPO) on the oxidative stress (OS) and inflammation caused by polymorphonuclear leukocytes (PMNLs) in end-stage renal failure patients undergoing continuous ambulatory peritoneal dialysis (CAPD) was investigated in vivo and in vitro. The studies were performed on isolated PMNLs from peripheral blood of CAPD patients before and following 6 weeks of EPO treatment and from healthy controls. OS was expressed by the rate of superoxide release from phorbol 12-myristate 13-acetate (PMA) stimulated isolated PMNLs and the inflammatory state was evaluated by PMNL counts of the enrolled subjects. Following 6 weeks of EPO treatment in CAPD patients, both the rate of superoxide release from PMNLs and PMNL counts fell significantly when compared with the pretreatment values. In vitro incubation of PMNLs from CAPD patients with increasing amounts of EPO displayed a significant reduction in their rates of superoxide release. EPO, by direct interaction with PMNLs, attenuated their primed state, causing reduction in oxidative stress and inflammation.

Keywords:
Continuous ambulatory peritoneal dialysis, Erythropoietin, Hemodialysis, Inflammation, Oxidative stress, Polymorphonuclear leukocytes, Superoxide release
1.
Kristal B, Shurtz-Swirski R, Shasha SM, Manaster J, Chezar J, Furmanov M, Weissman I, Sela S: Interaction between erythropoietin and peripheral polymorphonuclear leukocytes in hemodialysis patients. Nephron 1999;81:406–413.
2.
Sela S, Shurtz-Swirski R, Sharon R, Manaster J, Chezar J, Shkolnik G, Shapiro G, Shasha SM, Merchav S, Kristal B: The polymorphonuclear leukocyte – a new target for erythropoietin. Nephron 2001;88:205–210.
3.
Nourooz-Zadeh J: Effect of dialysis on oxidative stress in uraemia. Redox Rep 1999;4:17–22.
4.
Canestrari F, Buoncristiani U, Galli F, Giorgini A, Albertini MC, Carobi C, Pascucci M, Bossu M: Antioxidant activity and lipid peroxidation in erythrocytes and plasma of chronic ambulatory peritoneal dialysis patients. Clin Chim Acta 1995;234:127–136.
5.
Kristal B, Shurtz- Swirski R, Chezar J, Manaster J, Levy R, Shapiro G, Weissman I, Shasha SM, Sela S: Participation of peripheral polymorphonuclear leukocytes in oxidative stress and inflammation inpatients with essential hypertension. Am J Hypertens 1998;11:921–928.
6.
Shurtz-Swirski R, Sela S, Herskovits AT, Shasha SM, Shapiro G, Nasser L, Kristal B: Involvement of polymorphonuclear leukocytes in oxidative stress and inflammation in type 2 diabetes. Diabetes Care 2001;24:104–110.
© 2002 S. Karger AG, Basel
2002
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.